Evotec will pay a total consideration of up to $ 90m including potential earn outs in the next three years. The initial consideration upon closing is $ 60m subject to customary net debt and working capital adjustments. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co, Lilly Asia Ventures and the Bill & Melinda Gates Foundation. “With the integration of Just.Bio’s expertise in biologics and their outstanding human talent, we will accelerate our ability to build better molecules with cutting-edge technologies for our customers as well as our own pipeline. We warmly welcome the Just.Bio employees to the Evotec Group.” Dr Werner Lanthaler, Chief Executive Officer of Evotec. “Starting with a small group of creative and passionate employees, we've made remarkably fast progress building a state-of-the-art technology platform for expanding global access to biologics. Joining forces with Evotec will build upon these accomplishments and accelerate expansion of our advanced capabilities in Seattle, a growing hub of technology innovation. We are thrilled to be part of the excellent Evotec global team.” Dr James Thomas, EVP, Global Head, Biotherapeutics, President US Operations of Evotec.